Pouchitis
Drug research and approvals for pouchitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 6 studies of pouchitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 0 approved and 11 open orphan designations naming it.
- Recruiting worldwide: 6
- Trials authorized in Canada: 3
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 6 recruiting on ClinicalTrials.gov ↗- Etrasimod as Prevention of PouchitisNCT07486921 · Phase 2 · Maia Kayal · starts Jul 1, 2026
- GUselkumAb inteRvention and DIet evaluAtioN for PouchitisNCT06916390 · Phase 4 · Universitaire Ziekenhuizen KU Leuven · starts Apr 23, 2026
- A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic…NCT06443502 · Phase 3 · Takeda · starts Nov 19, 2024
- Fecal Microbiota Transplant for Patients With Chronic PouchitisNCT05829109 · Early Phase 1 · Maia Kayal · starts Oct 3, 2024
- Rifaximin for the Secondary Prevention of Recurrent PouchitisNCT06312683 · Phase 4 · University of North Carolina, Chapel Hill · starts Jul 1, 2024
- Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)NCT05938465 · Phase 1 / Phase 2 · Exegi Pharma, LLC · starts Nov 6, 2023
Drug Pipeline
3 in phase 3, 4 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Ustekinumab
- Phase 3 Interleukin-12 inhibitor
- Vedolizumab
- Phase 3 Integrin alpha-4/beta-7 inhibitor
- Alicaforsen
- Phase 3 Intercellular adhesion molecule-1 mRNA 3'UTR antisense inhibitor
- Charcoal, activated
- Phase 2
- Liraglutide
- Phase 2 Glucagon-like peptide 1 receptor agonist
- Tofacitinib
- Phase 2 Janus Kinase (JAK) inhibitor
- Vimekofusp
- Phase 2
- Metronidazole
- Phase 1 DNA inhibitor
- Fosfomycin
- Phase 1 UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor
- Maltodextrin
- Phase 1
How Its Trials Ended
41 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 12 whose ending is known, 17% met their primary endpoint, 8% missed it and 75% stopped early.
- Completed, result not reported1332%
- Ongoing922%
- Status unknown717%
- Stopped: other or unclear512%
- Met its primary endpoint25%
- Stopped: enrollment or feasibility25%
- Missed its primary endpoint12%
- Stopped: lack of efficacy12%
- Stopped: funding12%
Trials Authorized in Canada
Newest first; search them all in Canada trials| May 19, 2020 | A combined phase 2/3 12-week, randomized, double-blind, placebo-controlled study investigating the efficacy of amt-101 in subjects with chronic…AMT-101 | Applied Molecular Transport Inc. | Ongoing |
| Jan 18, 2019 | Randomized trial of fecal microbiota transplantation versus placebo for the induction of remission in patients with active pouchitisFecal microbiota for transplantation (fmt), human biotherapy (hbt) | Mcmaster University | Pending |
| May 5, 2016 | A randomized, double-blind, placebo-controlled phase 4 study to evaluate the efficacy and safety of entyvio (vedolizumab iv) in the treatment of chronic…Entyvio | Takeda Pharmaceuticals USA | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Apr 29, 2024 | (-)-Epigallocatechin 3-gallateTreatment of pouchitis | PharmassetX LLC | Designated |
| Nov 8, 2022 | Recombinant human interleukin-10 fusion proteinTreatment of pouchitis | Applied Molecular Transport, Inc. | Designated |
| Oct 18, 2022 | RifamycinTreatment of Pouchitis | Cosmo Technologies, Ltd. | Designated |
| Mar 15, 2021 | VedolizumabTreatment of Pouchitis | Takeda Development Center Americas, Inc. | Designated |
| Nov 2, 2020 | EXE-346, a Live Biotherapeutic Product (LBP), contains…Treatment of pouchitis | ExeGi Pharma, LLC. | Designated |
| Apr 26, 2011 | MetronidazoleTreatment of pouchitis | S.L.A. Pharma Limited (UK) | Designated |
| Sep 17, 2008 | MetronidazoleTreatment of pouchitis | Avivia Project BV | Designated |
| Dec 19, 2007 | Spherical carbon adsorbentTreatment of chronic pouchitis | Ocera Therapeutics, Inc. | Designated |
| Jun 14, 2005 | ClotrimazoleTopical treatment of children and adults with pouchitis | AesRx, LLC | Designated |
| Jan 15, 2002 | Lactic acid bacteria (Lactobacilli, Bifidobacteria, and…Treatment of active chronic pouchitis | VSL Pharmaceuticals, Inc. | Designated |
| Jan 15, 2002 | Lactic acid bacteria (Lactobacilli, Bifidobacteria, and…Prevention of disease relapse in patients with chronic pouchitis | VSL Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA